Corona Reinvents Sustainable Packaging by Launching Beer Pack Made Using Barley
Corona today launches a new, circular form of packaging for six-packs as part of its long-standing dedication to protecting the environment – harnessing surplus barley straw to create a truly sustainable paper packaging solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005586/en/
Corona's new barley straw packaging (Photo: Business Wire)
Corona, which has a deep connection with the natural world, is the first global brand to leverage technology and processes three years in development by AB InBev’s Global Innovation and Technology Center (GITEC). This ground-breaking technology reimagines how to use barley, giving the essential beer ingredient new life as a sustainable packaging solution.
Barley seed will continue to make the beer that consumers know and love. But barley straw, a leftover from farmers' harvests, will now be used through a unique pulping process built to handle its relative fragility.
Combined with 100% recycled wood fibers, this process creates a paper board to produce new packaging that is as strong and durable as a regular six-pack, but better for the planet – able to carry six cold beer bottles from the store fridge to the beach, but using far fewer resources along the way.
Turning barley straw into paper fiber uses 90% less water in its production than the traditional virgin wood process, along with less energy and fewer harsh chemicals. Using leftover barley straw is also far more productive than the equivalent area of woodland, and Corona sees this as one path forward to eliminate the need for virgin trees and raw material from their supply chain in the future.
Upon completion of the successful pilot, AB InBev, Corona’s parent company and the leading brewer in the world, will review rolling out the technology to other brands thereby increasing the potential positive environmental impact and the ability to influence the whole beverage industry.
Felipe Ambra, Global Vice President of Marketing, Corona, said: “Corona is a brand born at the beach. We’re deeply connected with nature and appreciate all that it has to offer, so we want to continue to do our part to protect it. Our deep reverence for nature is what inspires our vision to become a sustainability leader in the CPG industry, because we want everyone to be able to keep enjoying paradise.
Starting with our own packaging, we assessed where we could make changes within our production and supply chains to make a real difference. We are proud to announce this first step in reinventing the future of packaging for our industry.”
Keenan Thompson, Director of Packaging Innovation at AB InBev, said: “We’re excited to finally launch this new packaging innovation we’ve been developing over the past three years. At AB InBev we are continually pushing boundaries by developing scalable solutions. Today is a proud moment for us, not only are we providing an opportunity for farmers but we’re also delivering a more mindful solution to the consumer.”
The new packaging will launch today with an initial 10,000 six-packs rolling out as a pilot in Colombia in March, followed by Argentina later in 2021 as Corona looks to scale the new solution globally.
*****
Notes to Editor:
* when compared to traditional virgin wood pulping processes
Equivalent area of woodland is calculated with data from Washington State.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005586/en/
Contact information
For further information, please contact Emma Nathan
emma.nathan@3monkeyszeno.com
+44 20 7009 3100
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
